Actuate Therapeutics Initiates Randomized Trial of Elraglusib + Folfirinox as 1L Treatment of Advanced Pancreatic Cancer
Shots:
- The study evaluates elraglusib + folfirinox or losartan in patients with advanced pancreatic cancer across the University of Washington, University of Colorado Denver & Johns Hopkins University. The funding has been provided by Lustgarten Foundation
- The company plans to conduct studies in pediatric patients with refractory tumors for a neuroblastoma-specific clinical program
- Elraglusib is a GSK-3β inhibitor & developed for adults & children with advanced refractory cancers. The company collaborated with investigators at the Dana-Farber Cancer Institute & Brigham and Women’s Hospital for a P-II study to evaluate elraglusib + cytotoxic therapy for advanced salivary gland carcinomas
Ref: Globe Newswire | Image: Crunchbase
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com